Summary
Background To contain the spread of COVID-19, a cordon sanitaire was put in place in Wuhan prior to the Lunar New Year, on 23 January 2020, restricting travel to other parts of China. We assess the efficacy of the cordon sanitaire to delay the introduction and onset of local transmission of COVID-19 in other major cities in mainland China.
Methods We estimated the number of infected travellers from Wuhan to other major cities in mainland China from November 2019 to March 2020 using previously estimated COVID-19 prevalence in Wuhan and publicly available mobility data. We focused on Beijing, Chongqing, Hangzhou, and Shenzhen as four representative major cities to identify the potential independent contribution of the cordon sanitaire and holiday travel. To do this, we simulated outbreaks generated by infected arrivals in these destination cities using stochastic branching processes. We also modelled the effect of the cordon sanitaire in combination with reduced transmissibility scenarios representing the effect of local non-pharmaceutical interventions.
Findings In the four cities, given the potentially high prevalence of COVID-19 in Wuhan between Dec 2019 and early Jan 2020, local transmission may have been seeded as early as 2 - 8 January 2020. By the time the cordon sanitaire was imposed, simulated case counts were likely in the hundreds. The cordon sanitaire alone did not substantially affect the epidemic progression in these cities, although it may have had some effect in smaller cities.
Interpretation Our results indicate that the cordon sanitaire may not have prevented COVID-19 spread in major Chinese cities; local non-pharmaceutical interventions were likely more important for this.
Evidence before this study In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in Wuhan, China. In response to the outbreak, authorities enacted a cordon sanitaire in order to limit spread. Several studies have sought to determine the efficacy of the policy; a search of PubMed for “coronavirus AND (travel restrictions OR travel ban OR shutdown OR cordon sanitaire) AND (Wuhan OR China)” returned 24 results. However other studies have relied on reported cases to determine efficacy, which are likely subject to reporting and testing biases. Early outbreak dynamics are also subject to a significant degree of stochastic uncertainty due to small numbers of cases.
Added value of this study Here we use publicly-available mobility data and a stochastic branching process model to evaluate the efficacy of the cordon sanitaire to limiting the spread of COVID-19 from Wuhan to other cities in mainland China, while accounting for underreporting and uncertainty. We find that although travel restrictions led to a significant decrease in the number of individuals leaving Wuhan during the busy post-Lunar New Year holiday travel period, local transmission was likely already established in major cities. Thus, the travel restrictions likely did not affect the epidemic trajectory substantially in these cities.
Implications of all the available evidence A cordon sanitaire around the epicentre alone may not be able to reduce COVID-19 incidence when implemented after local transmission has occurred in highly connected neighbors. Local non-pharmaceutical interventions to reduce transmissibility (e.g., school and workplace closures) may have contributed more to the observed decrease in incidence in mainland China.
Competing Interest Statement
Akira Endo received a research grant from Taisho Pharmaceutical Co., Ltd. We declare no other competing interests.
Funding Statement
BJQ, CD, YL, and MJ were funded by the National Institute for Health Research (NIHR; 16/137/109). YL, PK, KP and MJ were funded by the Bill & Melinda Gates Foundation (INV-003174). HG was funded by the Department of Health and Social Care (ITCRZ 03010). TWR was funded by the Wellcome Trust (206250/Z/17/Z). CIJ was funded by the Global Challenges Research Fund (ES/P010873/1). CABP was funded by the NTD Modelling Consortium by the Bill and Melinda Gates Foundation (OPP1184344). SF and SC were funded by the Sir Henry Dale Fellowship (208812/Z/17/Z). RME was funded by Health Data Research UK (MR/S003975/1). This research was partly funded by the NIHR (16/137/109) using aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care. We would like to acknowledge the other members of the London School of Hygiene & Tropical Medicine CMMID COVID-19 modelling group, who contributed to this work. Their funding sources are as follows: Jon C Emery and Rein M G J Houben (European Research Council Starting Grant, Action Number #757699); Megan Auzenbergs and Kathleen O'Reilly (Bill and Melinda Gates Foundation, OPP1191821); Nicholas Davies (NIHR HPRU-2012-10096); Emily S Nightingale (Bill and Melinda Gates Foundation, OPP1183986); Kevin van Zandvoort (Elrha’s Research for Health in Humanitarian Crises [R2HC] Programme, UK Government [Department for International Development], Wellcome Trust, and NIHR); Thibaut Jombart (Research Public Health Rapid Support Team, NIHR Health Protection Research Unit Modelling Methodology); Arminder K Deol; W John Edmunds; Joel Hellewell, Sam Abbott, James D Munday, Nikos I Bosse and Sebastian Funk (Wellcome Trust 210758/Z/18/Z); Fiona Sun (NIHR; 16/137/109); Akira Endo (The Nakajima Foundation; The Alan Turing Institute); Alicia Rosello (NIHR: PR-OD-1017-20002); Amy Gimma (Global Challenges Research Fund ES/P010873/1); Simon R Procter (Bill and Melinda Gates Foundation, OPP1180644); Graham Medley (NTD Modelling Consortium by the Bill and Melinda Gates Foundation (OPP1184344); Adam J Kucharski (Wellcome Trust, 206250/Z/17/Z), and Gwen Knight (UK Medical Research Council, MR/P014658/1).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The mobility data was sourced from Baidu Haiyan migration dashboard. The code for this analysis is available on GitHub.
